Related Experiment Video
Updated: Aug 18, 2026

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
Published on: March 9, 2018
Efficacy and safety of generic amphotericin B in experimental pulmonary aspergillosis
Vidmantas Petraitis1, Ruta Petraitiene, Pengxin Lin
1Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Building 10, CRC, Rm. 1W-5740, 10 Center Dr., MSC 1100, Bethesda, Maryland 20892-1100, USA.
Abstract:
The recent shortage of the brand name drug Fungizone has necessitated a change to generic formulations of amphotericin B deoxycholate. Clinical trials cannot be conducted in a timely manner to provide data on the safety and efficacy of these formulations. We therefore compared generic amphotericin B and Fungizone for activity and safety in the treatment of experimental invasive pulmonary aspergillosis (IPA) in persistently neutropenic rabbits. Fungizone and generic amphotericin B are similar in efficacy, pharmacokinetics, and safety in the treatment of experimental IPA.
Related Concept Videos
Antifungal Agents
Fungal Phylum Ascomycota
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
